---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013176"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:17:43.863938+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025

## Summary
- Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.
- Trial evaluates THIO sequenced with CPI cemiplimab in advanced NSCLC patients after 2+ prior therapies.
- Corporate presentation posted to MAIA website on June 2, 2025, filed as Exhibit 99.2.
- Poster available on MAIA's website from June 2, 2025 onward.

## SEC filing metadata
- accession: 0001641172-25-013176
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/0001641172-25-013176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013176
- JSON: https://secwatch.observer/filing/0001641172-25-013176.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.